Medivir AB: Simeprevir Receives Positive CHMP Opinion For The Treatment Of Adults With Chronic Hepatitis C In The European Union

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Medivir AB (OMX: MVIR) (STO:MVIR-B) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC